These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Tumor-Infiltrating T Cell Receptor-Beta Repertoires are Linked to the Risk of Late Chemoradiation-Induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma. Wu L; Chung YL Int J Radiat Oncol Biol Phys; 2019 May; 104(1):165-176. PubMed ID: 30654091 [TBL] [Abstract][Full Text] [Related]
43. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma. Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644 [TBL] [Abstract][Full Text] [Related]
44. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy]. Binbin T; Lingying W; Manni H; Jusheng A; Ning L Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731 [TBL] [Abstract][Full Text] [Related]
45. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors]. Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774 [No Abstract] [Full Text] [Related]
46. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199 [TBL] [Abstract][Full Text] [Related]
47. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation. Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299 [TBL] [Abstract][Full Text] [Related]
48. Radiomics signature for dynamic changes of tumor-infiltrating CD8+ T cells and macrophages in cervical cancer during chemoradiotherapy. Huang K; Huang X; Zeng C; Wang S; Zhan Y; Cai Q; Peng G; Yang Z; Zhou L; Chen J; Chen C Cancer Imaging; 2024 Apr; 24(1):54. PubMed ID: 38654284 [TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505 [TBL] [Abstract][Full Text] [Related]
50. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy. Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645 [TBL] [Abstract][Full Text] [Related]
51. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811 [TBL] [Abstract][Full Text] [Related]
52. Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin. Arakaki Y; Ariga T; Heianna J; Shimoji Y; Nakasone T; Taira Y; Nakamoto T; Ooyama T; Kudaka W; Kaneshima I; Nishihira K; Mekaru K; Aoki Y In Vivo; 2020; 34(5):2739-2743. PubMed ID: 32871808 [TBL] [Abstract][Full Text] [Related]
53. TCR Repertoire Diversity of Peripheral PD-1 Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056 [TBL] [Abstract][Full Text] [Related]
54. Comparisons of survivals and toxicities between young and elderly patients with cervical cancer treated with definitive radiotherapy or concurrent chemoradiotherapy. Wang W; Liu X; Meng Q; Zhang F; Hu K Taiwan J Obstet Gynecol; 2019 May; 58(3):364-369. PubMed ID: 31122526 [TBL] [Abstract][Full Text] [Related]
55. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery. Yang J; Yang J; Cao D; Shen K; Ma J; Zhang F J Gynecol Oncol; 2020 Mar; 31(2):e16. PubMed ID: 31912674 [TBL] [Abstract][Full Text] [Related]
56. The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer: a systematic review and meta-analysis. Zhong L; Li K; Song L; Yin R J Obstet Gynaecol; 2022 Jul; 42(5):830-837. PubMed ID: 35148230 [TBL] [Abstract][Full Text] [Related]
57. The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer. Lee GD; Chung B; Song JS; Jang SJ; Kim HR Anticancer Res; 2021 Jun; 41(6):3193-3204. PubMed ID: 34083315 [TBL] [Abstract][Full Text] [Related]
58. Radio-induced apoptosis of peripheral blood CD8 T lymphocytes is a novel prognostic factor for survival in cervical carcinoma patients. Ordoñez R; Henríquez-Hernández LA; Federico M; Valenciano A; Pinar B; Lloret M; Bordón E; Rodríguez-Gallego C; Lara PC Strahlenther Onkol; 2014 Feb; 190(2):210-6. PubMed ID: 24362501 [TBL] [Abstract][Full Text] [Related]
59. Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study. Miyata Y; Ogo E; Abe T; Hirata H; Tsuda N; Ushijima K; Kawahara A; Akiba J; Obara H; Kakuma T Radiat Oncol; 2023 Feb; 18(1):40. PubMed ID: 36823665 [TBL] [Abstract][Full Text] [Related]
60. Definitive concurrent chemoradiotherapy in cervical cancer--a University of Malaya Medical Centre experience. Zamaniah WI; Mastura MY; Phua CE; Adlinda A; Marniza S; Rozita AM Asian Pac J Cancer Prev; 2014; 15(20):8987-92. PubMed ID: 25374241 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]